Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study

Authors

Christopher T. Ritchlin (ORCID: https://orcid.org/0000-0002-2602-1219)
Maria Sole Chimenti (ORCID: https://orcid.org/0000-0002-1343-1729)
F. Lavie (ORCID: https://orcid.org/0000-0002-5213-257X)
F. Nantel (ORCID: https://orcid.org/0000-0002-7970-3328)
Evan Leibowitz (ORCID: https://orcid.org/0000-0002-0041-6984)
Atul Deodhar (ORCID: https://orcid.org/0000-0002-2130-1246)
Emmanouil Rampakakis (ORCID: https://orcid.org/0000-0002-7427-8246)
Ennio Lubrano (ORCID: https://orcid.org/0000-0001-6189-5328)
Mohamed Sharaf (ORCID: https://orcid.org/0009-0003-9847-2996)

Institutions

University of Rome Tor Vergata (IT)
University of Molise (IT)
Johnson & Johnson (United States) (US)
Oregon Health & Science University (US)
University of Rochester Medical Center (US)
Johnson & Johnson (France) (FR)
JSS Medical Research (India) (IN)
Fondation de Nant (CH)
McGill University (CA)

Publication Details

Journal: Rheumatology and Therapy
Published: 2025-07-21
DOI: https://doi.org/10.1007/s40744-025-00777-3
Primary Topic: Spondyloarthritis Studies and Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Yale University
Gilead Sciences
Johnson and Johnson

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study

Christopher T. Ritchlin, Maria Sole Chimenti, F. Lavie, F. Nantel et al.

Jul 21, 2025

Rheumatology and Therapy

Spondyloarthritis Studies and Treatments

article

Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study

Christopher T. Ritchlin, Maria Sole Chimenti, F. Lavie, F. Nantel, Evan Leibowitz, Atul Deodhar, Emmanouil Rampakakis, Ennio Lubrano, Mohamed Sharaf

July 21, 2025article en

Abstract

No abstract available for this paper.

Rheumatology and TherapyVol. 12(5)

University of Rome Tor Vergata (IT), University of Molise (IT), Johnson & Johnson (United States) (US), Oregon Health & Science University (US), University of Rochester Medical Center (US), Johnson & Johnson (France) (FR), JSS Medical Research (India) (IN), Fondation de Nant (CH), McGill University (CA)

Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Yale University, Gilead Sciences, Johnson and Johnson

Zero hunger

Openalex Percentile: Top 72%

Spondyloarthritis Studies and Treatments

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study — Christopher T. Ritchlin, Maria Sole Chimenti, et al. · Rheumatology and Therapy (2025) | TGRS Research Map | TGRS